Treatment with the PI3K inhibitor Idelalisib (IC50, 1.5 μM), the BTK inhibitor Ibrutinib (IC50, 6 μM), the MALT1 proteolytic inhibitor MI2 (IC50, 0,56 μM), the NF-kB inhibitor Bay11-7082 (IC50, 13.4 μM) and two drugs currently used in the treatment of SMZL (bendamustine and fludarabine) reduced B-cell lymphoma cell survival, but to a much lesser extent than the chemical inhibitors of Lyn (Dasatinib, IC50, 33 nM) and Syk (p505-15, IC50, 264 nM) kinases (Fig. 7g). Here, BTK is linked to B-cell non-Hodgkin lymphoma.